14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ALAB vs MCHPP: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Astera Labs, Inc. (ALAB) is the stronger overall head-to-head candidate over Microchip Technology Incorporated Depositary Shares Each Representing a 1/20th Interest in a Share of 7.50% Series A Mandatory Convertible Preferred Stock (MCHPP) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ALAB carries a Unified Composite Score of 53.4/100 (HOLD) at $208.25 (31.0x Forward P/E, 25.5% operating margin), whereas MCHPP carries 57.1/100 (HOLD) at $52.64 (N/M Forward P/E, 21.6% operating margin).
Composite vs. Pillar Nuance: While MCHPP currently prints a higher short-term Unified Composite Score (57.1/100 HOLD vs. ALAB 53.4/100 HOLD), ALAB captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (25.5% vs. 21.6% operating margin) and revenue trajectory (+153.7% vs. +42.2% YoY).
Technical & Structure Timing Caution: ALAB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.4); meanwhile MCHPP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Microchip Technology Incorporated Depositary Shares Each Representing a 1/20th Interest in a Share of 7.50% Series A Mandatory Convertible Preferred Stock
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ALAB vs MCHPP. Trailing 12-month operating profitability (ALAB 25.5% vs MCHPP 21.6%) and valuation multiples (ALAB 31.0x vs MCHPP N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Investor FAQ ALAB vs MCHPP Key Questions & Quantitative Answers
As of Nov 16, 2026, Astera Labs, Inc. (ALAB) is the stronger overall head-to-head candidate over Microchip Technology Incorporated Depositary Shares Each Representing a 1/20th Interest in a Share of 7.50% Series A Mandatory Convertible Preferred Stock (MCHPP) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ALAB carries a Unified Composite Score of 53.4/100 (HOLD) at $208.25 (31.0x Forward P/E, 25.5% operating margin), whereas MCHPP carries 57.1/100 (HOLD) at $52.64 (N/M Forward P/E, 21.6% operating margin). Composite vs. Pillar Nuance: While MCHPP currently prints a higher short-term Unified Composite Score (57.1/100 HOLD vs. ALAB 53.4/100 HOLD), ALAB captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (25.5% vs. 21.6% operating margin) and revenue trajectory (+153.7% vs. +42.2% YoY). Technical & Structure Timing Caution: ALAB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.4); meanwhile MCHPP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ALAB leads the Growth & Scale pillar: ALAB posts +153.7% YoY revenue growth and +98.0% YoY earnings growth on $1.56B TTM revenue (73.9% gross margin, 25.5% operating margin), compared with MCHPP at +42.2% YoY revenue growth and N/A YoY earnings growth on $5.60B TTM revenue (62.7% gross margin, 21.6% operating margin). On trailing 12-month operating scale, ALAB generates $1.56B in USD-normalized revenue versus $5.60B for MCHPP. In operating R&D and SG&A reinvestment, ALAB deploys 48.4% of Rev ($753M) (0 90-day corporate R&D disclosures) versus 41.1% of Rev ($2.30B) (0 disclosures) for MCHPP.
ALAB screens cheaper on headline valuation multiples. ALAB trades at 31.0x Forward P/E, 90.0x Trailing P/E, N/M PEG, and 25.6x EV/Revenue (22.1% FCF margin), whereas MCHPP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (33.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ALAB (28.2% ROE) versus MCHPP (12.6% ROE) capital efficiency.
In options market volatility and institutional positioning, ALAB carries 89.7% implied volatility (31st %ile, Balanced (25th–60th %ile)), a 1.36x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (4.24β · 124% Vol realized risk). By comparison, MCHPP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.16β · 65% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Microchip Technology Incorporated Depositary Shares Each Representing a 1/20th Interest in a Share of 7.50% Series A Mandatory Convertible Preferred Stock (MCHPP) Research Suite
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.